Step 1: Intake & Referral Triage
Primary care referral notes and baseline labs are reviewed prior to scheduling to prioritize suspected active synovitis.
Rheumatology Specialty Practice ยท Sample template
Illustrative Rheumatology Care Pathways
Educational Clinical Scenarios & HIPAA Notice
To protect patient confidentiality under HIPAA and medical ethics standards, Rheumatology Specialty Practice does not publish identifiable patient medical histories. The pathways below illustrate standard clinical workflows. Verified, de-identified practice vignettes ([VERIFIED_CASE_STUDIES]) are pending medical director review and compliance sign-off.
Pathway 1: Early Symmetric Polyarthritis Evaluation
Patients referred for persistent morning stiffness lasting over an hour and swelling in the small joints of the hands benefit from structured early evaluation to prevent erosive joint changes.
Step 2: Clinical & Baseline Screening
Joint examination, baseline hand/foot radiographs, and pre-treatment infectious disease screening are completed.
Step 3: Shared Decision-Making & Follow-Up
Initiation of appropriate disease-modifying therapy with structured follow-up intervals to measure clinical response and medication tolerance.
Pathway 2: Transitioning from Acute Gout Flares to Preventive Control
Recurrent crystal arthritis often leads to urgent care visits without addressing underlying hyperuricemia. Our outpatient workflow bridges acute symptom control and long-term crystal dissolution.
Step 1: Diagnostic Confirmation
Review of prior flare history, serum urate trends, renal function, and joint aspiration findings where applicable.
Step 2: Prophylaxis & Gradual Titration
Coordinating anti-inflammatory flare prophylaxis while gradually titrating urate-lowering therapy toward guideline-informed serum targets.
Step 3: Comorbidity Coordination
Communicating medication adjustments with primary care and cardiology or nephrology teams managing concurrent blood pressure or kidney regimens.
Pathway 3: Clarifying an Positive ANA Referral
A positive antinuclear antibody (ANA) test frequently causes understandable anxiety. Our consultation pathway separates benign laboratory findings from evolving systemic autoimmune disease through thorough organ-system review, specific extractable nuclear antigen testing when indicated, and clear patient reassurance or monitoring plans.